Emiliano Calvo - Search Results : TheLancet.com

Search results for Emiliano Calvo in Authors

Please login above or register to save search alerts. Registration is free, takes no more than two minutes, and offers you many benefits.

	Type	Article Title (sort by relevance)	Author(s)	Date	Source	Cited By
1.	Articles	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06) Preview \| Summary \| Full Text \| PDF PFS and response rates were greater than those previously observed with gemcitabine and capecitabine or sorafenib monotherapy in patients with metastatic RCC. Adverse events were manageable in most patients. These findings provide preliminary confirmation of the synergistic activity of the chemo-switch concept seen in preclinical studies, and merit further exploration.	Dr Joaquim Bellmunt MD, José Manuel Trigo MD, Emiliano Calvo MD, Joan Carles MD, José L Pérez-Gracia MD, Jordi Rubió MD and others	Apr 2010	The Lancet Oncology, Vol. 11 No. 4 pp 350-357	3
2.	Correspondence	Hepatic artery chemotherapy and colorectal liver metastases Preview \| Full Text \| PDF Efficacy and compliance are two separate components related to how treatment works in the population, and they should not be routinely combined in a single intention-to-treat analysis.One of the major justifications for undertaking an intention-to-treat analysis in a randomised study is that, by ignoring compliance when the data are analysed, the way treatments will function in the population is suggested. When compliance shows great imbalance in a phase 3 study, however, this result counts against the treatment efficacy of the non-compliant group.	Emiliano Calvo , Manuel Sureda	May 17, 2003	The Lancet, Vol. 361 No. 9370 p 1743	0